TradingKey

• Trane Technologies reported strong Q1 2026 results exceeding expectations. • Bookings and backlog increased, leading to raised full-year guidance. • Analysts maintain positive ratings and price targets for TT.

• Vertiv beat Q1 2026 earnings estimates and raised full-year guidance. • AI demand and data center cooling acquisition boost Vertiv's position. • Analysts upgraded ratings and price targets for Vertiv shares.

• Parker-Hannifin reported record revenue and beat EPS estimates. • Stock fell due to guidance meeting, valuation, and insider selling. • Investors may have expected stronger future guidance.

• Booking Holdings cut revenue growth forecast due to Middle East conflict. • First-quarter results beat expectations, but outlook lowered. • Company sees headwinds continuing into the second quarter.

• Analyst upgrades and price target increases support AMD stock. • Intel's strong earnings signal demand for x86 CPUs in AI. • Upcoming earnings and AI accelerator ramp-up are anticipated.

• Altria's Q1 2026 EPS beat estimates, reaching $1.32. • Revenue exceeded projections, reaching $4.76 billion. • Full-year EPS guidance was reaffirmed, projecting $5.56-$5.72.

• Amgen stock gained 3.25% amid regulatory concerns and pipeline optimism. • FDA proposed Tavneos withdrawal due to effectiveness, data, and safety issues. • Anticipation for Q1 2026 earnings and pipeline developments fueled positive sentiment.

• Anheuser-Busch InBev (BUD) saw price increase due to Q1 2026 earnings anticipation. • Company plans $3 billion repurchase and approved 2025 dividend. • Analysts maintain "Moderate Buy" rating with positive price targets.

• Texas Instruments reported strong Q1 earnings and guidance, boosting stock. • Industrial and data center segments showed significant year-over-year growth. • Positive analyst sentiment and favorable semiconductor industry conditions support TXN.

• Rio Tinto reported strong Q1 2026 production, maintaining full-year guidance. • Favorable commodity outlook and analyst ratings support stock performance. • Institutional investment and operational efficiency drive positive sentiment.

TradingKey - As the U.S.-Iran war enters its ninth week, Bridgewater Associates founder Ray Dalio is urging investors to increase their gold holdings, recommending an allocation of 5% to 15% of their portfolios as global uncertainty has risen significantly. Since the outbreak of the conflict, spot gold prices have fallen by more than 10%. Compared to a nearly 70% gain for the full year last year, gold has risen only 5% year-to-date. Why, against this backdrop, does Dalio remain bullish on gold's performance?

• Corning's Q1 2026 results surpassed analyst estimates, boosting stock price. • Demand for AI and new solar products drives Optical Communications growth. • Company projects continued Q2 growth and extends "Springboard" plan to 2030.

• Analyst sentiment positive, price targets increased, buy ratings reiterated. • Strategic expansion into AI data centers and electrification fuels momentum. • Upcoming earnings, dividend increase, and spin-off signal financial health.

• Marvell's AI infrastructure market position is strengthening. • Acquisition of Polariton enhances optical technology portfolio. • Analysts maintain positive sentiment with price target upgrades.

• ARM Holdings stock rose, driven by AI demand and analyst upgrades. • Wells Fargo, Mizuho, and Needham analysts provided positive ratings and price targets. • ARM's AI chip designs and licensing business show growth potential.

• Seagate reported strong fiscal Q3 2026 results and forecast, exceeding expectations. • Robust demand for AI infrastructure and hyperscale data centers drives storage sector growth. • Analysts upgraded price targets, signaling strong confidence in Seagate's trajectory.

• AI disruption fears pressure SaaS sector and CRM stock. • Slack sues Microsoft for alleged anticompetitive practices. • Investors reduced stakes; analysts lowered price targets.

• Microsoft's Q1 2026 results surpassed expectations. • Higher 2026 capex guidance caused investor concern. • Macroeconomic data and sector trends pressured the stock.

• AbbVie exceeded Q1 2026 expectations with strong earnings and revenue. • Skyrizi and Rinvoq drove growth, offsetting Humira biosimilar impact. • AbbVie raised 2026 guidance; analysts upgraded stock ratings.

• Deere stock rose amid volatility with positive analyst sentiment. • Strong Q1 2026 earnings and raised full-year guidance support Deere. • Favorable long-term industry outlook and new technologies aid Deere.